The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 17, 2013
Filed:
May. 27, 2009
Hidetomo Furuyama, Kanagawa, JP;
Yasuhiro Goto, Tokyo, JP;
Nobuhiko Kawanishi, Ibaraki, JP;
Mark E. Layton, Harleysville, PA (US);
Takashi Mita, Ibaraki, JP;
Yoshio Ogino, Ibaraki, JP;
Yu Onozaki, Kanagawa, JP;
Michael A. Rossi, Limerick, PA (US);
Toshihiro Sakamoto, Ibaraki, JP;
Philip E. Sanderson, Valley Forge, PA (US);
Jiabing Wang, Chalfont, PA (US);
Hidetomo Furuyama, Kanagawa, JP;
Yasuhiro Goto, Tokyo, JP;
Nobuhiko Kawanishi, Ibaraki, JP;
Mark E. Layton, Harleysville, PA (US);
Takashi Mita, Ibaraki, JP;
Yoshio Ogino, Ibaraki, JP;
Yu Onozaki, Kanagawa, JP;
Michael A. Rossi, Limerick, PA (US);
Toshihiro Sakamoto, Ibaraki, JP;
Philip E. Sanderson, Valley Forge, PA (US);
Jiabing Wang, Chalfont, PA (US);
Merck Sharp & Dohme Corp., Rahway, NJ (US);
MSD K.K., Chiyoda-Ku, Tokyo, JP;
Abstract
The instant invention provides for substituted [1,2,4]triazolo[4,3-a]-1,5-naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms, preferably Akt1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity, especially Akt1 by administering the compound to a patient in need of treatment of cancer.